Breaking News Instant updates and real-time market news.

FCX

Freeport McMoRan

$12.19

0.7 (6.09%)

, DOCU

DocuSign

$53.27

0.67 (1.27%)

10:18
02/13/19
02/13
10:18
02/13/19
10:18

Fly Intel: Top five analyst upgrades

Catch up on today's top five analyst upgrades with this list compiled by The Fly: 1. Freeport McMoRan (FCX) upgraded to Overweight from Equal Weight at Morgan Stanley with analyst Piyush Sood saying his firm's Metals & Mining team expects copper market tightness to emerge beginning in Q2, given falling global production, low visible inventories and improved demand from China and Freeport's earnings sensitivity to copper is still the highest among its peers. 2. DocuSign (DOCU) upgraded to Buy from Hold at Deutsche Bank with analyst Karl Keirstead saying that after speaking with four large e-signature customers, three using DocuSign and one using Adobe Sign, the analyst believes a "more constructive call on DocuSign shares is now warranted." 3. Bloom Energy (BE) upgraded to Outperform from Market Perform at Raymond James with analyst Pavel Molchanov saying shares are down about 36% since the IPO in July 2018, including a 24% drop since mid-January, the latter due in large part to selling pressure following lockup expiration. 4. Shopify (SHOP) upgraded to Outperform from Sector Perform at RBC Capital with analyst Ross MacMillan saying he anticipates the company to return to new merchant growth this year given its international opportunity and easier comps. 5. Myovant Sciences (MYOV) upgraded to Overweight from Equal Weight at Barclays with analyst Geoffrey Meacham saying his firm's women's health survey suggests a "robust potential market" for new treatment options for endometriosis and uterine fibroids. The analyst also raised his price target for the shares to $25 from $22. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.

FCX

Freeport McMoRan

$12.19

0.7 (6.09%)

DOCU

DocuSign

$53.27

0.67 (1.27%)

BE

Bloom Energy

$10.00

0.4 (4.17%)

SHOP

Shopify

$173.61

-1.9 (-1.08%)

MYOV

Myovant Sciences

$19.20

(0.00%)

  • 13

    Feb

  • 13

    Feb

  • 14

    Feb

  • 25

    Feb

  • 04

    Mar

FCX Freeport McMoRan
$12.19

0.7 (6.09%)

02/13/19
02/13/19
UPGRADE
Target $14

Overweight
Morgan Stanley bullish on copper, upgrades Freeport McMoRan to Overweight
As previously reported, Morgan Stanley analyst Piyush Sood upgraded Freeport McMoRan to Overweight from Equal Weight, noting that his firm's Metals & Mining team expects copper market tightness to emerge beginning in Q2, given falling global production, low visible inventories and improved demand from China. Freeport's earnings sensitivity to copper is still the highest among its peers, said Sood, who sees the stock emerging as "the go-to large-cap stock for exposure to a copper price rally." Concerns about Freeport's ability to ramp production from 2019-21 are overblown, added the analyst, who lowered his price target on the shares to $14 from $16, citing a lower multiple to reflect the overall compression in multiples across equities and management's newly disclosed expectations around costs.
02/12/19
MSCO
02/12/19
UPGRADE
Target $14
MSCO
Overweight
Freeport McMoRan upgraded to Overweight from Equal Weight at Morgan Stanley
Morgan Stanley analyst Piyush Sood upgraded Freeport McMoRan to Overweight but lowered his price target to $14 from $16.
02/12/19
JEFF
02/12/19
NO CHANGE
Target $25
JEFF
Buy
Jefferies sees 'strong recovery' for Freeport McMoRan after 2019
Until recently, investor sentiment regarding Freeport McMoRan had been negative following a challenging 2018, Jefferies analyst Christopher LaFemina tells investors in a research note. Further, the analyst believes the consensus view is that 2019 will be another difficult year for Freeport due to low volumes, high unit costs, high capex and a low copper price. LaFemina agrees that 2019 will be a "trough year" for Freeport, but he also expects a "strong recovery" in EBITDA and free cash flow after 2019. As such, the analyst reiterates a Buy rating on the shares with a $25 price target.
01/09/19
01/09/19
INITIATION

Fly Intel: Top five analyst initiations
Catch up on today's top five analyst initiations with this list compiled by The Fly: 1. CarGurus (CARG) initiated with an Outperform at Oppenheimer. 2. Callaway Golf (ELY) and Acushnet Holdings (GOLF) were initiated with an Equal Weight at Stephens. 3. MVB Financial (MVBF) initiated with a Market Perform at Keefe Bruyette. 4. U.S. Steel (X) initiated with a Market Perform at Cowen. 5. Freeport McMoRan (FCX) initiated with a Neutral at Credit Suisse. This list is just a portion of The Fly's analyst coverage. To see The Fly's full Street Research coverage, click here.
DOCU DocuSign
$53.27

0.67 (1.27%)

02/12/19
DBAB
02/12/19
UPGRADE
DBAB
Buy
DocuSign upgraded to Buy from Hold at Deutsche Bank
Deutsche Bank analyst Karl Keirstead upgraded DocuSign to Buy from Hold.
01/28/19
KEYB
01/28/19
INITIATION
Target $59
KEYB
Overweight
DocuSign initiated with an Overweight at KeyBanc
KeyBanc analyst Rob Owens started DocuSign with an Overweight rating and $59 price target. The e-signature market has begun to accelerate on broadening adoption, Owens tells investors in a research note. He believes DocuSign is well positioned to penetrate a "disproportionate share" of the market's greater than $25B opportunity.
01/30/19
WBLR
01/30/19
NO CHANGE
WBLR
Outperform
21st Century IDEA Act a catalyst for DocuSign, says William Blair
The 21st Century Integrated Digital Experience Act, which was signed into law on December 20, 2018, set into motion legislation that should accelerate e-signature adoption within the U.S. federal government, William Blair analyst Justin Furby tells investors in a research note. The analyst believes digital signature usage within the federal government has lagged that of the private sector. He estimates the U.S. federal government opportunity is "conservatively" anywhere from $280M to $500M-plus of total addressable market. As such, the analyst views the passing of the 21st Century IDEA Act as an incremental catalyst for DocuSign (DOCU) that should provide an additional growth lever over the next couple of years. He keeps an Outperform rating on the shares. Further, the analyst sees minimal, if any impact to the competitive landscape in the wake of Dropbox's (DBX) Acquisition of HelloSign. DocuSign has an integration with Dropbox that will continue going forward, says Furby. He remains a buyer of DocuSign shares and sees the potential for "significant" estimate revisions in the coming quarters.
02/13/19
DBAB
02/13/19
UPGRADE
Target $65
DBAB
Buy
Deutsche Bank upgrades DocuSign to Buy after channel checks
Deutsche Bank analyst Karl Keirstead last night upgraded DocuSign to Buy from Hold and raised his price target for the shares to $65 from $50. After speaking with four large e-signature customers, three using DocuSign and one using Adobe Sign, the analyst believes a "more constructive call on DocuSign shares is now warranted." While "hardly cheap," DocuSign's valuation is "not unreasonable given the growth profile," Keirstead tells investors in a research note. Further, he points out that key share lock-up expiration dates are now in the past.
BE Bloom Energy
$10.00

0.4 (4.17%)

02/13/19
RAJA
02/13/19
UPGRADE
RAJA
Outperform
Bloom Energy upgraded to Outperform from Market Perform at Raymond James
10/31/18
10/31/18
UPGRADE
Target $24

Neutral
Bloom Energy upgraded to Neutral ahead of quarterly results at Credit Suisse
As previously reported, Credit Suisse analyst Michael Weinstein upgraded Bloom Energy to Neutral from Underperform, with a $24 price target. The analyst cited recent sharp underperformance, as he expects in-line system/price guidance for the company's debut earnings call.
02/13/19
02/13/19
UPGRADE
Target $13

Outperform
Bloom Energy upgraded to Outperform on valuation at Raymond James
As previously reported, Raymond James analyst Pavel Molchanov upgraded Bloom Energy to Outperform from Market Perform, with a $13 price target. The analyst notes that shares are down about 36% since the IPO in July 2018, including a 24% drop since mid-January, the latter due in large part to selling pressure following lockup expiration. With the broad contours of the story little-changed over the past seven months, the stock's intense sentiment-driven volatility has created what the analyst views as an attractive entry point.
02/06/19
FBCO
02/06/19
UPGRADE
FBCO
Outperform
Bloom Energy upgraded to Outperform from Neutral at Credit Suisse
SHOP Shopify
$173.61

-1.9 (-1.08%)

02/13/19
WELS
02/13/19
NO CHANGE
Target $195
WELS
Outperform
Shopify price target raised to $195 from $175 at Wells Fargo
Wells Fargo analyst Timothy Willi raised his price target for Shopify to $195 from $175 following better than expected Q4 results that were driven by a combination of strong merchant acquisition trends, adoption of merchant solutions, and robust spending trends during the holiday season, including record-setting Cyber Monday/Black Friday sales. The analyst reiterates an Outperform rating on the shares.
02/13/19
KEYB
02/13/19
NO CHANGE
Target $197
KEYB
Overweight
Shopify price target raised to $197 from $182 at KeyBanc
KeyBanc analyst Monika Garg raised her price target for Shopify to $197 from $182 after the company posted "strong" Q4 results, and issued in-line 2019 revenue guidance and lower operating income guidance. The analyst reiterates an Overweight rating on the shares.
02/13/19
DADA
02/13/19
NO CHANGE
Target $210
DADA
Buy
Shopify price target raised to $210 from $150 at DA Davidson
DA Davidson analyst Tom Forte raised his price target on Shopify to $210 and kept his Buy rating, saying the change accounts for his updated EBITDA margin projection rising to 40% long term from 3.6% in 2018. The analyst notes that the management's plan to ramp investment spending for 2019 reflects the company's "important growth efforts - international expansion and Shopify Plus".
02/13/19
ROTH
02/13/19
NO CHANGE
Target $200
ROTH
Buy
Shopify price target raised to $200 from $180 at Roth Capital
Roth Capital analyst Darren Aftahi raised his price target for Shopify to $200 from $180 after Q4 outperformed, as strong Holiday sales and merchant adds resulted in about 54% year over year revenue growth and Plus penetration improved to about 25%. The analyst reiterates a Buy rating on the shares.
MYOV Myovant Sciences
$19.20

(0.00%)

09/13/18
JPMS
09/13/18
INITIATION
Target $39
JPMS
Overweight
Myovant Sciences initiated with an Overweight at JPMorgan
JPMorgan analyst Eric Joseph started Myovant Sciences with an Overweight rating and $39 price target. The analyst views Myovant as a "differentiated offering" within the oral gonadotropin-releasing hormone space. Further, he believes the company's advanced prostate cancer program offers pipeline optionality that is not fully reflected in the current valuation.
10/26/18
GSCO
10/26/18
INITIATION
Target $25
GSCO
Neutral
Myovant Sciences initiated with a Neutral at Goldman Sachs
Goldman Sachs analyst Dana Flanders started Myovant Sciences with a Neutral rating and $25 price target. The analyst's due diligence suggests a "likely slow build" for the antagonist class. Further, Flanders anticipates "minimal clinical differentiation" between the agents in development. The analyst views Myovant's growth opportunity as attractive but sees competitive markets.
02/13/19
LEHM
02/13/19
UPGRADE
Target $25
LEHM
Overweight
Myovant Sciences upgraded to Overweight from Equal Weight at Barclays
Barclays analyst Geoffrey Meacham upgraded Myovant Sciences to Overweight and raised his price target for the shares to $25 from $22.
02/13/19
LEHM
02/13/19
UPGRADE
Target $25
LEHM
Overweight
Barclays upgrades Myovant to Overweight on bullish women's health survey
Barclays analyst Geoffrey Meacham upgraded Myovant Sciences to Overweight from Equal Weight and raised his price target for the shares to $25 from $22. The analyst says his firm's women's health survey suggests a "robust potential market" for new treatment options for endometriosis and uterine fibroids. Respondents to the survey reported positive experiences with Orilissa and noted increasing patient interest in new therapies, Meacham tells investors in a research note. He believes Myovant will benefit from these market dynamics.

TODAY'S FREE FLY STORIES

ETFC

E-Trade

$47.45

0.88 (1.89%)

17:33
02/17/19
02/17
17:33
02/17/19
17:33
Conference/Events
E-Trade to hold Education Day »

Education Day to be held…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Feb

PFE

Pfizer

$42.41

0.45 (1.07%)

12:56
02/17/19
02/17
12:56
02/17/19
12:56
Hot Stocks
Pfizer, EMD Serono announce publication of Phase 3 data for BAVENCIO plus INLYTA »

Merck KGaA, which…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 20

    Feb

  • 18

    May

MRK

Merck

$79.84

0.9 (1.14%)

, PFE

Pfizer

$42.41

0.45 (1.07%)

12:48
02/17/19
02/17
12:48
02/17/19
12:48
Hot Stocks
Merck presents results from Phase 3 KEYNOTE-426 study »

Merck (MRK) announced…

MRK

Merck

$79.84

0.9 (1.14%)

PFE

Pfizer

$42.41

0.45 (1.07%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 20

    Feb

  • 11

    Apr

  • 18

    May

AVEO

Aveo Pharmaceuticals

$0.62

0.0092 (1.51%)

12:42
02/17/19
02/17
12:42
02/17/19
12:42
Hot Stocks
Aveo Pharmaceuticals presents TIVO-3 trial topline results »

Aveo Oncology announced…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

ARDM

Aradigm

$0.00

(0.00%)

12:34
02/17/19
02/17
12:34
02/17/19
12:34
Hot Stocks
Aradigm announces plans for reorganization under Chapter 11 »

Aradigm has filed for…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

AMZN

Amazon.com

$1,608.88

-13.47 (-0.83%)

, XPO

XPO Logistics

$52.01

-7.535 (-12.65%)

13:26
02/16/19
02/16
13:26
02/16/19
13:26
Periodicals
Amazon a risk for almost every stock/sector, Barron's says »

Amazon (AMZN) is eating…

AMZN

Amazon.com

$1,608.88

-13.47 (-0.83%)

XPO

XPO Logistics

$52.01

-7.535 (-12.65%)

KR

Kroger

$29.50

0.54 (1.86%)

FAST

Fastenal

$62.97

0.61 (0.98%)

GWW

Grainger

$316.63

4.9 (1.57%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 16

    Feb

  • 20

    Feb

  • 20

    Feb

  • 20

    Feb

  • 03

    Mar

  • 18

    Mar

YETI

Yeti

$22.85

0.97 (4.43%)

13:20
02/16/19
02/16
13:20
02/16/19
13:20
Periodicals
Yeti stock has 60% upside, Barron's says »

Yeti Holdings stock…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

L

Loews

$46.67

0.785 (1.71%)

13:14
02/16/19
02/16
13:14
02/16/19
13:14
Periodicals
Investors can love Loews, Barron's says »

Loews is a $15B…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 03

    Mar

  • 28

    May

EQIX

Equinix

$421.53

1.16 (0.28%)

, COR

CoreSite Realty

$102.69

0.625 (0.61%)

13:10
02/16/19
02/16
13:10
02/16/19
13:10
Periodicals
Equinix, CoreSite Realty among stocks to play data-center boom, Barron's says »

Data-center stocks may…

EQIX

Equinix

$421.53

1.16 (0.28%)

COR

CoreSite Realty

$102.69

0.625 (0.61%)

IRM

Iron Mountain

$35.13

-0.14 (-0.40%)

INXN

Interxion

$64.65

0.81 (1.27%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Feb

  • 25

    Feb

  • 26

    Mar

  • 26

    Mar

NOK

Nokia

$6.31

0.015 (0.24%)

, ERIC

Ericsson

$9.36

0.015 (0.16%)

13:07
02/16/19
02/16
13:07
02/16/19
13:07
Periodicals
A U.S. ban of Huawei may benefit Ericsson, Samsung, Barron's says »

The next salvo in the…

NOK

Nokia

$6.31

0.015 (0.24%)

ERIC

Ericsson

$9.36

0.015 (0.16%)

SSNLF

Samsung

$0.00

(0.00%)

CSCO

Cisco

$49.45

1.05 (2.17%)

JNPR

Juniper

$27.12

0.16 (0.59%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Feb

  • 26

    Feb

  • 27

    Feb

  • 28

    Feb

COP

ConocoPhillips

$70.13

1.04 (1.51%)

, MUR

Murphy Oil

$29.23

0.59 (2.06%)

13:00
02/16/19
02/16
13:00
02/16/19
13:00
Periodicals
Dividend investors should look to oil stocks for big yields, Barron's says »

Energy stocks aren't…

COP

ConocoPhillips

$70.13

1.04 (1.51%)

MUR

Murphy Oil

$29.23

0.59 (2.06%)

CVX

Chevron

$119.30

1.19 (1.01%)

VLO

Valero

$84.34

0.75 (0.90%)

XOM

Exxon Mobil

$77.74

1.47 (1.93%)

MRO

Marathon Oil

$17.07

0.15 (0.89%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 04

    Mar

  • 07

    Mar

  • 18

    Mar

  • 22

    May

  • 28

    May

AMZN

Amazon.com

$1,608.88

-13.47 (-0.83%)

12:45
02/16/19
02/16
12:45
02/16/19
12:45
Periodicals
Protestors against NY's Amazon HQ2 got math wrong, Barron's says »

On Thursday, Amazon…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 16

    Feb

  • 20

    Feb

  • 20

    Feb

  • 03

    Mar

  • 18

    Mar

ICE

IntercontinentalExchange

$75.49

-0.46 (-0.61%)

, NDAQ

Nasdaq

$87.74

0.56 (0.64%)

12:28
02/16/19
02/16
12:28
02/16/19
12:28
Periodicals
Investors interested in U.S. cannabis companies face challenges, Barron's says »

Investors interested in…

ICE

IntercontinentalExchange

$75.49

-0.46 (-0.61%)

NDAQ

Nasdaq

$87.74

0.56 (0.64%)

CGC

Canopy Growth

$47.54

1.49 (3.24%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 18

    Feb

  • 28

    May

  • 15

    Feb

AMD

AMD

$23.68

0.55 (2.38%)

, INTC

Intel

$51.64

0.85 (1.67%)

08:43
02/16/19
02/16
08:43
02/16/19
08:43
On The Fly
Week in review: How Trump's policies moved stocks »

Catch up on the top…

AMD

AMD

$23.68

0.55 (2.38%)

INTC

Intel

$51.64

0.85 (1.67%)

MRVL

Marvell

$18.82

-0.37 (-1.93%)

MCHP

Microchip

$91.10

0.49 (0.54%)

MU

Micron

$41.99

-0.23 (-0.54%)

NVDA

Nvidia

$157.22

2.69 (1.74%)

QCOM

Qualcomm

$51.97

0.42 (0.81%)

TXN

Texas Instruments

$107.55

0.57 (0.53%)

TWTR

Twitter

$31.23

0.28 (0.90%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 20

    Feb

  • 21

    Feb

  • 25

    Feb

  • 07

    Mar

  • 07

    Mar

  • 25

    Mar

  • 26

    Mar

  • 28

    May

  • 04

    Jun

  • 05

    Jun

AMGN

Amgen

$188.31

1.6 (0.86%)

, ALPMY

Astellas Pharma

$0.00

(0.00%)

04:55
02/16/19
02/16
04:55
02/16/19
04:55
Conference/Events
American Society of Clinical Oncology to hold a symposium »

2019 ASCO Genitourinary…

AMGN

Amgen

$188.31

1.6 (0.86%)

ALPMY

Astellas Pharma

$0.00

(0.00%)

AZN

AstraZeneca

$40.92

0.93 (2.33%)

BAYRY

Bayer

$0.00

(0.00%)

BMY

Bristol-Myers

$51.64

0.81 (1.59%)

CALA

Calithera Biosciences

$5.35

0.14 (2.69%)

CLVS

Clovis

$25.44

(0.00%)

DNA

Bought by RHHBY

$0.00

(0.00%)

ESALY

Eisai

$0.00

(0.00%)

EXEL

Exelixis

$22.26

-0.05 (-0.22%)

IMMU

Immunomedics

$14.23

0.225 (1.61%)

INO

Inovio

$3.70

0.01 (0.27%)

MRK

Merck

$79.84

0.9 (1.14%)

MYOV

Myovant Sciences

$21.48

0.1 (0.47%)

MYGN

Myriad Genetics

$31.41

0.53 (1.72%)

NH

NantHealth

$0.60

(0.00%)

NVS

Novartis

$89.89

0.865 (0.97%)

PFE

Pfizer

$42.41

0.45 (1.07%)

PGNX

Progenics

$4.87

0.13 (2.74%)

SGEN

Seattle Genetics

$71.48

2.92 (4.26%)

SNY

Sanofi

$42.51

0.94 (2.26%)

TYME

Tyme Technologies

$3.19

0.055 (1.76%)

AVEO

Aveo Pharmaceuticals

$0.62

0.0092 (1.51%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 16

    Feb

  • 16

    Feb

  • 19

    Feb

  • 20

    Feb

  • 25

    Feb

  • 26

    Feb

  • 26

    Feb

  • 28

    Feb

  • 07

    Mar

  • 11

    Mar

  • 22

    Mar

  • 11

    Apr

  • 28

    Apr

  • 18

    May

  • 20

    May

WES

Western Gas Partners

$49.52

0.38 (0.77%)

, WGP

Western Gas Equity

$32.38

0.2 (0.62%)

19:30
02/15/19
02/15
19:30
02/15/19
19:30
Recommendations
Western Gas Partners, Western Gas Equity analyst commentary at MUFG »

MUFG raises price targets…

WES

Western Gas Partners

$49.52

0.38 (0.77%)

WGP

Western Gas Equity

$32.38

0.2 (0.62%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 15

    Feb

  • 15

    Feb

  • 04

    Mar

PXD

Pioneer Natural

$145.33

2.27 (1.59%)

19:19
02/15/19
02/15
19:19
02/15/19
19:19
Recommendations
Pioneer Natural analyst commentary at MUFG »

Pioneer Natural price…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    May

ZTS

Zoetis

$95.38

2.16 (2.32%)

18:42
02/15/19
02/15
18:42
02/15/19
18:42
Hot Stocks
Zoetis CEO says: 'Diagnostics are more important in animals than humans' »

In an interview on…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

JNJ

Johnson & Johnson

$136.40

2.13 (1.59%)

18:22
02/15/19
02/15
18:22
02/15/19
18:22
Hot Stocks
Johnson & Johnson CEO: 'We ended 2018 with great results' »

In an interview on…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 18

    Feb

  • 25

    Feb

  • 25

    Feb

  • 06

    Mar

WIN

Windstream

$3.37

0.2 (6.31%)

, UNIT

Uniti Group

$20.00

0.53 (2.72%)

18:18
02/15/19
02/15
18:18
02/15/19
18:18
Periodicals
Court says Windstream defaulted on bonds in 2015, Bloomberg says »

A court has ruled that…

WIN

Windstream

$3.37

0.2 (6.31%)

UNIT

Uniti Group

$20.00

0.53 (2.72%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Feb

  • 28

    Feb

BHVN

Biohaven Pharmaceutical

$45.32

1.36 (3.09%)

18:14
02/15/19
02/15
18:14
02/15/19
18:14
Hot Stocks
Biohaven treatment of multiple system atrophy granted FDA orphan designation »

According to a post on…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

AMGN

Amgen

$188.31

1.6 (0.86%)

18:11
02/15/19
02/15
18:11
02/15/19
18:11
Hot Stocks
Amgen treatment of Acute Myeloid Leukemia granted FDA orphan designation »

According to a post on…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

CE

Celanese

$100.19

1.19 (1.20%)

18:02
02/15/19
02/15
18:02
02/15/19
18:02
Hot Stocks
Celanese announces Acetyl Intermediates price increases in China »

Celanese will increase…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

WIN

Windstream

$3.37

0.2 (6.31%)

, UNIT

Uniti Group

$20.00

0.53 (2.72%)

17:58
02/15/19
02/15
17:58
02/15/19
17:58
Periodicals
Court says Windstream defaulted on bonds in 2015, Bloomberg says »

A court has ruled that…

WIN

Windstream

$3.37

0.2 (6.31%)

UNIT

Uniti Group

$20.00

0.53 (2.72%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Feb

  • 28

    Feb

GLD

SPDR Gold Shares

$124.81

0.77 (0.62%)

17:41
02/15/19
02/15
17:41
02/15/19
17:41
Hot Stocks
SPDR Gold Shares holdings fall to 793.03MT from 796.85MT »

This is the lowest level…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.